Knowledge

NHS England’s transition to Value-Based Procurement (VBP) shifts purchasing decisions from lowest price to long-term value, focusing on patient outcomes, lifecycle costs, and sustainability. This model improves healthcare efficiency, reduces hidden expenses, and encourages higher-quality medical equipment adoption, creating a more resilient and outcome-driven procurement system across hospitals, suppliers, and global healthcare markets. Medical Devices […]

Performance-based contracting ties payments to uptime, diagnostic accuracy, and clinical outcomes, shifting risk to vendors and aligning procurement with Total Cost of Ownership and long-term value; HHG GROUP data shows growing demand for uptime guarantees and outcome-linked fees as buyers move from price-first to value-first purchasing. Bio Medical Procurement Strategy: Balancing Innovation with Budgetary Constraints

Refurbished medical equipment is becoming a core strategy in healthcare procurement as providers balance cost control, sustainability, and access to advanced technology. With the market projected to reach $20.96 billion in 2026 and growing rapidly, hospitals increasingly rely on certified pre-owned systems to reduce capital expenses, improve environmental performance, and maintain high-quality diagnostic and surgical

Agentic AI will autonomously manage vendor vetting, real-time risk monitoring, and coordinated response playbooks—reducing procurement cycle times and preventing supply disruptions while operating under human-defined guardrails. HHG GROUP’s platform experience shows these agents cut downtime and speed secure trades by automating multi-step workflows. Bio Medical Procurement Strategy: Balancing Innovation with Budgetary Constraints What is Agentic

Standardizing the purchasing process focuses organizations on repeatable workflows, governance, and lifecycle costs—yielding more durable savings and less clinical disruption than SKU-only consolidation. Health systems auditing spend outliers and aligning purchased services and specialty equipment procurement reduce fragmented spend and total cost of ownership while improving supplier accountability and clinical uptime. HHG GROUP’s platform data

The FDA’s 510(k) clearance of the Cala kIQ Plus in April 2026 marks a significant advancement in non-invasive tremor management. This next-generation wearable features adaptive calibration and new therapy modes, offering a more personalized and effective treatment for patients with Essential Tremor (ET) and Parkinson’s Disease (PD) tremor. It represents a leap forward in accessible,

Trinity Capital’s $50 million growth capital investment in Cala Health represents a pivotal vote of confidence in the future of non-invasive neuromodulation. This infusion will accelerate the commercial scale-up of Cala’s TAPS therapy, a wearable device designed to treat essential tremor, expanding patient access and driving next-generation innovation in a high-growth medical device segment. Medical

Presented at the American Academy of Neurology 2026 Annual Meeting, data from Cala’s Poster P5-005 demonstrated that the kIQ system’s novel variable waveforms achieved significantly higher responder rates in treating essential tremor. This advancement represents a meaningful step in personalized neuromodulation, offering a more adaptable and potentially more effective therapy by dynamically adjusting stimulation patterns

The NeurologyLive TAPSA 2026 report underscores a pivotal shift in bioelectronic medicine, moving decisively from generic stimulation to personalized neuromodulation. This evolution, exemplified by devices like the kIQ Plus, tailors therapy to an individual’s unique neurophysiological signature for superior outcomes in conditions like tremor. It represents a fundamental rethinking of how medical devices interact with

Neurology groups wanting to add TAPS‑based neuromodulation often run into the same problem: the device feels like a high‑risk capital purchase because Medicare reimbursement rules look contradictory, coding is murky, and billing staff are unsure whether the Cala kIQ and similar TAPS stimulators qualify as durable medical equipment (DME) under Part B or get pushed